Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: =98.35%
Anisomycin (Wuningmeisu C, NSC76712, AI3-50846, Flagecidin), a naturally occurring bacterial antibiotic isolated from Streptomyces griseolus, is a novel, potent, and specific activator (agonist) of JNK (c-Jun N-terminal Kinase) with potential antineoplastic activity. It is also a potent and reversible inhibitor of protein synthesis in eukaryotic organisms. It does this by binding to and inhibiting the activity of the 60S ribosomal subunit's peptidyl transferase.
Targets |
JNK; DNA synthesis
|
---|---|
ln Vitro |
Anisomycin (3 μM) decreases MDA16 and MDA-MB-468 cell protein synthesis and MDA-MB-468 cell colony formation. In MDA-MB-468 cultures, anisomycin increases the number of apoptotic cells, but not in MDA16 cultures. In MDA-MB-468 cells, anisomycin activates JNK phosphorylation. [2] Anisomycin inhibits cell growth in U251 and U87 cells in a concentration- and time-dependent manner with an IC50 (48 h) value of 0.233 and 0.192 μmol/L, respectively. In U251 and U87 cells, respectively, anisomycin (4 μM) induces 21.5% and 25.3% of apoptosis proportion and activates p38 MAPK and JNK while inactivating ERK1/2. In U251 and U87 cells, anisomycin (4 μM) decreases the level of PP2A/C subunit in a time-dependent manner. [3] The proliferation of EAC cells is inhibited by anisomycin in a concentration-dependent manner. [4]
Aim: To examine the effects of anisomycin on glioma cells and the related mechanisms in vitro. Methods: The U251 and U87 human glioblastoma cell lines were tested. The growth of the cells was analyzed using a CCK-8 cell viability assay. Apoptosis was detected using a flow cytometry assay. The expression of proteins and phosphorylated kinases was detected using Western blotting. Results: Treatment of U251 and U87 cells with anisomycin (0.01-8 μmol/L) inhibited the cell growth in time- and concentration-dependent manners (the IC(50) values at 48 h were 0.233±0.021 and 0.192±0.018 μmol/L, respectively). Anisomycin (4 μmol/L) caused 21.5%±2.2% and 25.3%±3.1% of apoptosis proportion, respectively, in U251 and U87 cells. In the two cell lines, anisomycin (4 μmol/L) activated p38 MAPK and JNK, and inactivated ERK1/2. However, neither the p38 MAPK inhibitor SB203580 (10 μmol/L) nor the JNK inhibitor SP600125 (10 μmol/L) prevented anisomycin-induced cell death. On the other hand, anisomycin (4 μmol/L) reduced the level of PP2A/C subunit (catalytic subunit) in a time-dependent manner in the two cell lines. Treatment of the two cell lines with the PP2A inhibitor okadaic acid (100 nmol/L) caused marked cell death. Conclusion: Anisomycin induces glioma cell death via down-regulation of PP2A catalytic subunit. The regulation of PP2A/C exression by anisomycin provides a clue to further study on its role in glioma therapy.[3] |
ln Vivo |
Anisomycin (5 mg/kg) administered intraperitoneally significantly slows the growth of Ehrlich ascites carcinoma (EAC), resulting in a 60% mouse survival rate 90 days after EAC inoculation.[4]
The aim of this study was to explore the potential of anisomycin to treat tumors in vivo and its mechanism(s) of action. The results showed that peritumoral administration of anisomycin significantly suppressed Ehrlich ascites carcinoma (EAC) growth resulting in the survival of approximately 60% of the mice 90 days after EAC inoculation. Enhancement of infiltrating lymphocytes was noted in the tumor tissue, which was dramatically superior to adriamycin. The growth inhibitory rate of EAC cells was enhanced with increasing concentrations of anisomycin, following an enhanced apoptotic rate. The total apoptotic rate induced by 160 ng/ml of anisomycin was higher when compared to that induced by 500 ng/ml of adriamycin. DNA breakage and nanostructure changes were also noted in the EAC cells. The levels of caspase-3 mRNA, caspase-3 and cleaved-caspase-3 proteins in the anisomycin‑treated EAC cells were augmented in a dose- and time-dependent manner, following the activation of caspase-8 and caspase-9, which finally triggered PARP cleavage. The cleaved-caspase-3, cleaved-caspase-8 and cleaved-caspase-9 proteins were mainly localized in the nuclei of the cells. These results indicate that anisomycin efficaciously represses in vitro and in vivo growth of EAC cells through caspase signaling, significantly superior to the effects of adriamycin. This suggests the potential of anisomycin for the treatment of breast cancer. |
Enzyme Assay |
In 6-well plates, 500,000 cells are seeded per well and left to incubate overnight. Following that, test compounds or DMSO as a vehicle control are incubated with cells for 1 hour at a final concentration of 1% v/v. To label developing polypeptide chains, puromycin (final concentration: 18 μM) is added, and cells are then incubated for an additional 10 min. By incubating cells without puromycin, background labeling is ascertained. Following a HBSS wash, scraping cell harvest, and 5-minute, 300-g centrifugation, cells are isolated. 0.5 mL of 50 mM DTT containing phosphatase inhibitors is used to resuspend the cells, and they are then incubated at 95°C for 10 min. Samples are then immediately frozen in liquid nitrogen and kept at -20°C until blotted. Samples (20–30 g of protein per sample) are blotted onto a PVDF membrane. Anti-phospho-Thr183/Tyr185-JNK antibody is applied to the membrane after it has been blocked and incubated at 4 °C overnight. An infrared scanner is used to detect secondary antibodies that are used to label the primary antibody. Anti-phospho-JNK antibody fluorescence signal strength is background adjusted and loaded-normalized.
Inhibition of protein synthesis per se does not potentiate the stress-activated protein kinases (SAPKs; also known as cJun NH2-terminal kinases [JNKs]). The protein synthesis inhibitor anisomycin, however, is a potent activator of SAPKs/JNKs. The mechanism of this activation is unknown. We provide evidence that in order to activate SAPK/JNK1, anisomycin requires ribosomes that are translationally active at the time of contact with the drug, suggesting a ribosomal origin of the anisomycin-induced signaling to SAPK/JNK1. In support of this notion, we have found that aminohexose pyrimidine nucleoside antibiotics, which bind to the same region in the 28S rRNA that is the target site for anisomycin, are also potent activators of SAPK/JNK1. Binding of an antibiotic to the 28S rRNA interferes with the functioning of the molecule by altering the structural interactions of critical regions. We hypothesized, therefore, that such alterations in the 28S rRNA may act as recognition signals to activate SAPK/JNK1. To test this hypothesis, we made use of two ribotoxic enzymes, ricin A chain and alpha-sarcin, both of which catalyze sequence-specific RNA damage in the 28S rRNA. Consistent with our hypothesis, ricin A chain and alpha-sarcin were strong agonists of SAPK/JNK1 and of its activator SEK1/MKK4 and induced the expression of the immediate-early genes c-fos and c-jun. As in the case of anisomycin, ribosomes that were active at the time of exposure to ricin A chain or alpha-sarcin were able to initiate signal transduction from the damaged 28S rRNA to SAPK/JNK1 while inactive ribosomes were not[1]. |
Cell Assay |
EAC cells are plated in 96-well plates at a density of 10,000 cells/well and 200 µL of medium for the assay. Anisomycin is applied to the cells in a variety of concentrations for 48 hours. As a positive control, adriamycin (500 ng/mL) is used. MTT is added to every well at a concentration of 0.5 mg/mL. The formazan product of the MTT reduction is dissolved in DMSO 4 hours later, and an absorbance measurement at 570 nm is made using a Model 680 microplate reader.
Cell viability assay [3] A cell viability assay was performed using the cell counting kit-8 (CCK-8) according to the manufacturer's instructions. The cells were plated in 96-well plates in 200 μL of culture media with various concentrations of anisomycin. The cells were then cultured at 37 °C in a humidified incubator containing 95% air and 5% CO2. After 48 h, the CCK-8 solution was added to each well and incubated for 1 h in the incubator. The absorbance measurement was performed at 450 nm using an enzyme-linked immunosorbent assay plate reader. Apoptosis assay by flow cytometry [3] Cells were plated in 10-cm culture dishes, allowed to adhere for 8 h and then exposed to anisomycin for 48 h at 37 °C. After 48 h, the cells were collected by trypsinization, centrifuged (3500 r/min for 5 min), and washed twice with PBS. The cells were fixed in 1 mL of 70% ethanol, pelleted by centrifugation (3500 r/min for 5 min), rinsed twice with PBS, Then, cells were incubated for 15 min at room temperature with annexin V-FITC and propidium iodide before analysis with a FACSAria III flow cytometer. |
Animal Protocol |
Balb/c mice of both sexes (4-5 weeks old)
84, 99, 116, 136 or 160 mg/kg; 0.2 mL per mouse Intravenously injected through mouse tail vein |
Toxicity/Toxicokinetics |
rat LD50 oral 72 mg/kg Antibiotics and Chemotherapy, 5(490), 1955
rat LD50 intraperitoneal 345 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD; LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Antibiotics and Chemotherapy, 5(490), 1955 rat LD50 subcutaneous 230 mg/kg Antibiotics and Chemotherapy, 5(490), 1955 rat LD50 intravenous 167 mg/kg BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD; LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION Antibiotics and Chemotherapy, 5(490), 1955 mouse LD50 oral 148 mg/kg Antibiotics and Chemotherapy, 5(490), 1955 |
References | |
Additional Infomation |
(-)-anisomycin is an antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. It has a role as an antiparasitic agent, a DNA synthesis inhibitor, a protein synthesis inhibitor, an antineoplastic agent, an antimicrobial agent, a bacterial metabolite and an anticoronaviral agent. It is a monohydroxypyrrolidine and an organonitrogen heterocyclic antibiotic.
Anisomycin (sometimes known as flagecidin), is an antibiotic retrieved from the bacteria Streptomyces griseolus. This drug acts to inhibit bacterial protein and DNA synthesis. Anisomycin has been reported in Streptomyces hygrospinosus and Streptomyces with data available. An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin was identified in a screen of clinical compounds as a drug that kills breast cancer cells (MDA16 cells, derived from the triple negative breast cancer cell line, MDA-MB-468) that express high levels of an efflux pump, ABCB1. We show the MDA16 cells died by a caspase-independent mechanism, while MDA-MB-468 cells died by apoptosis. There was no correlation between cell death and either protein synthesis or JNK activation, which had previously been implicated in anisomycin-induced cell death. In addition, anisomycin analogues that did not inhibit protein synthesis or activate JNK retained the ability to induce cell death. These data suggest that either a ribosome-ANS complex is a death signal in the absence of JNK activation or ANS kills cells by binding to an as yet unidentified target.[2] |
Molecular Formula |
C14H19NO4
|
|
---|---|---|
Molecular Weight |
265.3
|
|
Exact Mass |
265.131
|
|
Elemental Analysis |
C, 63.38; H, 7.22; N, 5.28; O, 24.12
|
|
CAS # |
22862-76-6
|
|
Related CAS # |
|
|
PubChem CID |
253602
|
|
Appearance |
White to off-white solid powder
|
|
Density |
1.2±0.1 g/cm3
|
|
Boiling Point |
398.7±42.0 °C at 760 mmHg
|
|
Melting Point |
140-141ºC
|
|
Flash Point |
194.9±27.9 °C
|
|
Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
|
Index of Refraction |
1.558
|
|
LogP |
0.42
|
|
Hydrogen Bond Donor Count |
2
|
|
Hydrogen Bond Acceptor Count |
5
|
|
Rotatable Bond Count |
5
|
|
Heavy Atom Count |
19
|
|
Complexity |
302
|
|
Defined Atom Stereocenter Count |
3
|
|
SMILES |
O(C(C([H])([H])[H])=O)[C@]1([H])[C@]([H])(C([H])([H])N([H])[C@]1([H])C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])OC([H])([H])[H])O[H]
|
|
InChi Key |
YKJYKKNCCRKFSL-RDBSUJKOSA-N
|
|
InChi Code |
InChI=1S/C14H19NO4/c1-9(16)19-14-12(15-8-13(14)17)7-10-3-5-11(18-2)6-4-10/h3-6,12-15,17H,7-8H2,1-2H3/t12-,13+,14+/m1/s1
|
|
Chemical Name |
[(2R,3S,4S)-4-hydroxy-2-[(4-methoxyphenyl)methyl]pyrrolidin-3-yl] acetate
|
|
Synonyms |
Wuningmeisu C; NSC 76712; AI3 50846; anisomycin; 22862-76-6; Flagecidin; (-)-Anisomycin; TCMDC-125504; (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate; Upjohn 204t3; (2R,3S,4S)-2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate; NSC-76712; AI-350846; NSC76712; AI350846; Flagecidin
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO+corn oil: 5mg/mL |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.7693 mL | 18.8466 mL | 37.6932 mL | |
5 mM | 0.7539 mL | 3.7693 mL | 7.5386 mL | |
10 mM | 0.3769 mL | 1.8847 mL | 3.7693 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.